Of the 6382 patients with hormone receptor-positive disease, 56.2% received adjuvant endocrine treatment in line with the Dutch treatment guideline stating that patients with favorable tumor characteristics (grade 1 up to 2 cm and grade 2 up to 1 cm) do not receive adjuvant endocrine treatment as the absolute survival benefit is very limited in patients with a low-risk tumor. Here, NR4A1 is linked to neoplasm.